Cargando…
The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2)
BACKGROUND: Lianhuaqingke (LHQK) has been approved for the treatment of acute tracheobronchitis and exerts a broad-spectrum antiviral effect in our previous study. METHODS: Acute pneumonia caused by HCoV-229E was modeled in BALB/c mice. The anti-viral effect of LHQK was assessed by measuring the lun...
Autores principales: | Wang, Mingye, Li, Wenyan, Cui, Wenwen, Hao, Yuanyuan, Mi, Yao, Wang, Hongtao, Hou, Yunlong, Jia, Zhenhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521501/ https://www.ncbi.nlm.nih.gov/pubmed/34663385 http://dx.doi.org/10.1186/s13020-021-00513-3 |
Ejemplares similares
-
Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021) -
Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007) -
HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006) -
Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012) -
Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)